Sign Out
At the present, there are limited data on possible drug interactions with Rituximab. In CLL patients, co administration with Rituximab did not appear to have an effect on the pharmacokinetics of Fludarabine or Cyclophosphamide, in addition; there was no apparent effect of Fludarabine and Cyclophosphamide on the pharmacokinetics of Rituximab.
Patients with human anti-mouse antibody (HAMA) or human anti-chimeric antibody (HACA) titters may develop allergic or hypersensitivity reactions when treated with other diagnostic or therapeutic monoclonal antibodies.
The tolerability of simultaneous or sequential combination of Rituximab with agents, other than CHOP chemotherapy, which are liable to cause depletion of normal B-cells is not well defined.
